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A recent clinical trial in patients with hemophilia B has suggested that adeno-associated virus (AAV)
capsid-specific cytotoxic T lymphocytes (CTLs) eliminated AAV-transduced hepatocytes and resulted in ther-
apeutic failure. AAV capsids elicit a CTL response in animal models; however, these capsid-specific CTLs fail
to kill AAV-transduced target cells in mice. To better model the human clinical trial data in mice, we
introduced an immunodominant epitope derived from ovalbumin (OVA; SIINFEKL) into the AAV capsid and
tested CTL-mediated killing of AAV2-transduced target tissues in vivo. Initially, in vitro experiments demon-
strated both classical class I and cross-presentation of the OVA antigen, following endogenous expression or
AAV2-OVA vector transduction, respectively. Furthermore, an OVA-specific CTL response was elicited after
muscular or systemic injection of the AAV2-OVA vector. Finally, CTL reactivity was enhanced in mice with
established SIINFEKL-specific immunity after AAV2-OVA/1 anti-trypsin (AAT) administration. Most im-
portantly, these OVA-specific CTLs decreased AAT expression in mice treated with AAV2-OVA/AAT vector that
followed a time course mimicking uncoating kinetics of AAV2 transduction in OVA-immunized mice. These
results demonstrate that AAV capsid-derived antigens elicit CD8 CTL reactivity, and these CTLs eliminated
AAV-transduced target cells in mice. Notably, this model system can be exploited to study the kinetics of capsid
presentation from different serotypes of AAV and permit the design of novel strategies to block CTL-mediated
killing of AAV-transduced cells.
Adeno-associated virus (AAV) is a single-stranded DNA
parvovirus. Its replication relies on coinfection of a helper virus
such as adenovirus or herpesvirus. In the absence of a helper
virus, AAV establishes latency to integrate into the AAVS1
site of host chromosome 19 (11). The genome of AAV is 4.7
kb and contains two open reading frames encoding replication
proteins and structural capsid proteins (21). The capsid pro-
teins (VP) are composed of VP1, VP2, and VP3. The VP3
protein is the major structural component and constitutes
nearly 80% of the virion shell with an overall ratio of 1:1:8 for
VP1, VP2, VP3, respectively. While VP2 is thought to be
nonessential for AAV transduction (30), the VP1 subunit con-
tains a phospholipase A2 domain required for infectivity (9).
Recombinant AAV (rAAV) vectors require only the 145-bp
terminal repeats of the AAV genome in cis and all other viral
factors supplied in trans for production (18). rAAV vectors
have rapidly gained popularity in gene therapy applications
and have proven effective in preclinical studies/clinical trials
for a number of diseases (20, 31, 33).
AAV vectors mount a potent humoral immune response
against capsid in animals and human. However, AAV vectors
only contain the therapeutic gene flanked by two 145-bp AAV
terminal repeats devoid of any AAV genes(23). In addition,
AAV initiates long-term stable therapeutic gene expression in
animal models (3–5, 17, 31). Based on these observations AAV
has been thought to be relatively nonimmunogenic regarding
the induction of cytotoxic T lymphocytes (CTLs) specific for
capsid proteins. In spite of all of these observations, the recent
clinical trial for hemophilia B (F9) gene therapy has otherwise
suggested that AAV2 capsid initiates cell-mediated immunity
that eliminates the AAV2 encoding F9 (AAV2/F9) vector
transduced liver cells (15). Against this backdrop, numerous
attempts to replicate aforementioned observations in animal
models have been made. Preliminary results from these studies
support direct presentation and cross-presentation of the
AAV2 capsid in animal models (6, 12, 13, 22, 29). However,
capsid-specific CTLs did not eliminate AAV2-transduced tar-
get cells in mice (12, 13, 29), inconsistent with observations
made in a clinical trial for hemophilia B with AAV2/F9 gene
therapy. A potential explanation for this discrepancy is the
weak immunogenicity of the AAV2 capsid in mice. Accord-
ingly, we hypothesized that incorporation of a peptide epitope
into the AAV2 capsid would increase immunogenicity of the
rAAV and therefore could be exploited to mimic events on-
going in humans and study approaches to block capsid-specific
CTL reactivity in mice.
We chose to introduce the MHC-H2Kb-restricted SIIN
FEKL peptide derived from ovalbumin (OVA) into AAV2
capsid. Integration of the OVA epitope into AAV capsids
elicited a specific CTL response. Most importantly, after ad-
ministration of genetically engineered AAV2 vectors into
OVA peptide-immunized mice, OVA-specific CTL reactivity
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was further enhanced, thereby limiting transgene expression in
vivo. The modified vector described herein is a potentially
valuable tool for future studies focused on developing strate-
gies to evade capsid-specific CTL-mediated elimination of
AAV-transduced target cells in animal models.
MATERIALS AND METHODS
Cells and virus. AAV virus production was previously described (34). The
virus titer was determined by Southern dot blot. To rule out the possibility of
minimal Cap-OVA plasmid construct in the virus preps, we have tested for
AAV-OVA virus using an alkaline gel and did not find the Cap2-OVA plasmid
contamination in the virus preps after blotting with transgene-specific probe and
pCap2-OVA backbone probe.
Mice. C57BL/6 mice and BALB/c mice were purchased from Jackson Labo-
ratory (Bar Harbor, ME). The OT-1/Rag-1 mouse is transgenic for an H2Kb-
restricted T-cell receptor that recognizes the OVA-derived SIINFEKL peptide
and is deficient in the recombinase reactivating gene 1 (Rag-1 gene); therefore,
this mouse does not develop mature T or B cells expressing endogenous recep-
tors (Taconic Farms, Germantown, NY). All mice were maintained in a specific
pathogen-free facility at the University of North Carolina at Chapel Hill. The
University of North Carolina Institutional Animal Care and Use Committee
approved all procedures.
Construction of recombinant plasmids. The SIINFEKL epitope was cloned
into AAV2’s HI loop by substitution of amino acids (aa) 658 to 665 of capsid by
PCR with two pairs of primers, i.e. the primers F1 (5-CACGTGACTGGCAA
AGACTCATC) and R1 (5-GTTGATTATACTAGGATTCGCAGGTACCG
GGG) and the primers F2 (5-TTTGAAAAACTGTTTGCTTCCTTCATCACAC
AGTACTC) and R2 (5-GACCATGATTACGCCAAGCTCG); boldface
represents the OVA SIINFEKL nucleotide sequence. The PCR products from
primers F1R1 and F2R2 were digested with BsiWI and NotI, respectively. pXR2-
OVA was generated by insertion of digested PCR products into pXR2. The
Cap2-OVA fragment from pXR2-OVA with SwaI and NotI cohesive ends was
cloned into the pTR/CBA-1 anti-trypsin (AAT) backbone digested with EcoRI
(blunted) and NotI to form pTR/CBA-Cap2-OVA.
Peptides. AMQMLKETI (human immunodeficiency virus type 1 [HIV-1]
gag24 199-207) and SIINFEKL (OVA 257-264) were synthesized in the Univer-
sity of North Carolina at Chapel Hill Microprotein Sequencing and Peptide
Synthesis Facility and were 98% pure. Peptides were dissolved in dimethyl
sulfoxide at a concentration of 20 mg/ml and stored at 20°C.
Transfection. Nearly confluent 293 cells in a six-well plate were transfected
with 10 g of the respective plasmids using Lipofectamine 2000 according to
manufacturer’s instruction (Invitrogen). After 24 h, cells were used for interac-
tion with spleen cells from OT-1 mice.
Flow cytometry. 293 cells transfected with plasmids encoding H2Kb and
pAAV2-OVA were cocultured with 106 spleen cells were costained with a fluo-
rescein isothiocyanate (FITC)-labeled rabbit anti-mouse CD69 antibody (BD
Pharmingen) and an anti-CD8-phycoerythrin (PE) antibody (BD Pharmingen)
for 1 h at 4°C on ice. Cells were then washed and analyzed by flow cytometry. The
antibody isotype control was also included for each experiment.
Tetramer staining. OVA-specific tetramers were prepared as described by
Altman et al. (1). Briefly, H2Kb monomers were folded by the addition of the
OVA (SIINFEKL) peptide and -microglobulin subunit overnight in folding
buffer. Folded monomers were purified by using size exclusion and then biotin-
ylated using biotin and BirA enzyme (Avidity). Tetramers were assembled by
adding biotin-conjugating H2Kb monomers with streptavidin-PE (eBioscience)
24 h before use.
Spleen cells were cultured with 10 g of SIINFEKL/ml overnight. After wash-
ing, spleen cells were then incubated with a PE-labeled H2Kb-SIINFEKL tet-
ramers for 30 min at room temperature and then washed three additional times.
Spleen cells were incubated with FITC-conjugated rat anti-mouse CD8 antibody
for 30 min at 4°C. After washing, cells were analyzed by flow cytometry.
Intracellular IFN- staining. OT-1 spleen cells (106) were cocultured with
293/Kb cells overnight. Cells were incubated with 5 M/ml brefeldin A (BD
Pharmingen) for 5 h, stained with a FITC-conjugated anti-CD8 antibody, and
then fixed with Cytofix/Cytoperm (BD Pharmingen). Cells were then incubated
with a PE-conjugated anti-gamma interferon (IFN-	) antibody, washed, and
analyzed by flow cytometry.
Immunization. Dendritic cells (DCs) were generated as described before (12).
For immunization, mature DCs (106/ml) were pulsed with SIINFEKL or HIV
gag 24 (AMQMLKETI) peptides at 10 g/ml for 2 h at 37°C. A total of 5 
 105
DCs were then injected into C57BL/6 mice via tail vein three times at weekly
intervals (24).
For AAV2 immunization, 2 
 1011 particles of AAV2-OVA vector were
injected into C57BL/6 mice intramuscularly (i.m.) or intravenously (i.v.). Six
weeks later in vitro (tetramer staining for spleen cells) or in vivo CTL assays were
carried out.
In vivo CTL assay. An in vivo CTL assay was carried out as described by Chen
et al. with minor modifications (6). A total of 107 spleen cells from naive
syngeneic mice were incubated with either high (5 M) or low (0.5 M) con-
centrations of carboxyfluorescein succinimidyl ester (CFSE) in phosphate-buff-
ered saline at room temperature for 12 min. CFSE labeling was stopped by the
addition of fetal bovine serum to a final concentration of 20% (vol/vol). After the
cells were washed, CFSEhigh cells were incubated with 10 g of peptide/ml at
37°C for 1 h, whereas CFSElow cells were incubated in medium only. The
AMQMLKETI peptide was used as a negative control to pulse a separate
population of CFSEhi cells. After labeling and peptide pulsing, both populations
of target cells were washed and mixed together in ice-cold phosphate-buffered
saline, 107 cells of each population i.v. injected into mice. Spleen cells were
prepared 24 h later and analyzed by flow cytometry. The percent specific lysis was
determined by the ratio of recovered non-peptide-treated control spleen cells to
peptide-sensitized spleen cells (e.g., percentage of CFSElow cells/percentage of
CFSEhigh cells). The percent specific lysis (%) equaled 100 
 (1  [ratio of cells
recovered from naive mice/ratio of cells recovered from infected mice]).
Luciferase imaging. Six weeks after intramuscular (i.m.) injection of AAV2-
OVA/luc into BALB/c mice, the imaging was performed by using Xenogen
system.
ELISA for human AAT. Details for AAT detection by enzyme-linked immu-
nosorbent assay (ELISA) were described as previously (12).
Statistical analysis. The Student t test was used to perform statistical analysis.
Differences were considered statistically significant at P  0.05.
RESULTS
H2Kb-SIINFEKL complexes are detected on the surfaces of
cells transfected with the Cap2-OVA plasmid construct. The
OVA epitope SIINFEKL induces a strong CTL response in
C57BL/6 mice and is commonly used to investigate CTL-me-
diated immune responses. Accordingly, this immunodominant
epitope was inserted into a tolerant position of the AAV2
capsid: the HI loop. The HI loop has been shown to tolerate
insertions or substitution without a loss of function including
AAV virion assembly, receptor binding, and host range (7, 19).
Our previous work has demonstrated that a 4-aa linker inser-
tion at residue 649 just before the HI loop does not affect virus
yield and infectivity compared to wild-type AAV2 vectors (19).
To further characterize the HI loop for gene targeting pur-
poses, we swapped the HI loop of AAV2 with HI loops from
serotypes 1 and 8. A similar virus yield was achieved. All
viruses from wild-type AAV2 and mutants with AAV1 and
eight HI loops substitution had similar infectivities and hepa-
rin-binding capacities (7). Oligonucleotides encoding the
SIINFEKL epitope were cloned into the AAV2 HI loop by
substitution of aa 658 to 665 of capsid to generate the construct
pCap2-OVA. To determine whether the OVA epitope in the
context of Cap2-OVA was synthesized, processed, and pre-
sented, splenic SIINFEKL-specific OT-1 CD8 T cells were
cocultured with H2Kb-expressing human embryonic kidney
cells (293 cells) transfected with the pCap2-OVA plasmid con-
struct. After coculture with pCap2-OVA-transfected 293 cells,
9.52% and 2.57% of OT-1 CD8 T cells expressed the activa-
tion marker CD69 and intracellular IFN-	, respectively (Fig.
1). In contrast, no significant increase in the frequency of OT-1
CD8 T cells expressing CD69 or intracellular IFN-	 was
detected upon coculture with 293 cells transfected with Cap2
compared to wild-type 293 cells (Fig. 1). These results dem-
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onstrate that the SIINFEKL peptide in the context of Cap2-
OVA is processed and presented to T cells.
H2Kb-SIINFEKL complexes are detected on the surface of
cells transduced with AAV2-OVA in vitro. Next, we tested
whether an infectious AAV virion could be assembled using
the Cap2-OVA gene using a standard triple transfection
method. AAV2 particles were packaged with either green flu-
orescent protein (GFP), AAT or firefly luciferase (Luc) cDNA.
Compared to wild-type AAV2 capsid, similar titers of pack-
aged Cap2-OVA were obtained as determined by Southern dot
blot analysis (data not shown). In addition, a similar frequency
of transduced 293 cells was detected for the respective pack-
aged AAV recombinants regardless of the encoded transgenes
(Fig. 2).
To determine whether the OVA epitope expressed by the
AAV virion was efficiently processed and presented, H2Kb-
expressing 293 cells were transduced with AAV2-OVA/AAT
at 105 particles/cell and subsequently cocultured with splenic
OT-1 CD8 T cells. The frequency of OT-1 CD8 T cells
expressing CD69 and intracellular IFN-	 was increased 8-
fold upon coculture with 293 cells transduced with AAV2-
OVA/AAT relative to cultures containing 293 cells transduced
with AAV2/AAT or mock-transfected cells (Fig. 3). This result
further demonstrates that the SIINFEKL epitope in the con-
text of AAV2 capsid protein is processed and presented to
SIINFEKL-specific CD8 T cells.
Immunization with AAV2-OVA vector induces an OVA-spe-
cific CTL response in vivo. It has been reported that i.m.
injection of AAV2 vector elicits a capsid-specific CTL response
in mice (14, 29). To test this in our model system, 2 
 1011
particles of AAV2-OVA/AAT were injected i.m. into C57BL/6
mice, and 6 weeks later the induction of SIINFEKL-specific
CD8 T cells was examined via tetramer staining. In AAV2-
OVA/AAT-immunized mice, 2.73% of splenic CD8 T cells
stained with H2Kb-OVA tetramer, which in turn was 10-fold
increased relative mice injected with AAV2 (0.25%) or left
untreated (0.27%) (Fig. 4). Consistent with this observation,
CTL-mediated killing of SIINFEKL-pulsed target cells was
increased in mice immunized with AAV2-OVA but not AAV2
or in animals left untreated (Fig. 4B). This result demonstrates
that administration of AAV2-OVA induces a CTL response
specific for the SIINFEKL peptide.
Injection of AAV2-OVA i.v. also elicited a CTL response
specific for the SIINFEKL peptide. C57BL/6 mice received
FIG. 1. OVA epitope presentation in cells transfected with the
chimeric AAV2-OVA capsid gene (pAAV2-OVA). 293 cells with 80%
to 90% confluent in a six-well plate were transfected with 5 g of a
plasmid expressing H2Kb and 5 g of the genes encoding the AAV2
capsid or the chimeric AAV2 capsid harboring the OVA epitope
(pCap2-OVA). The next day, transfected 293 cells were incubated with
spleen cells from OT-1 mice for 24 h. Then, OT-1 spleen cells were
stained for CD8 and either CD69 or intracellular IFN-	 and analyzed
by flow cytometry. The data represent the results of one of three
different experiments.
FIG. 2. Transduction efficiency of AAV2-OVA vector in vitro. 293
cells in a 24-well plate were transduced with different AAV2-OVA
vector. After 24 h, 293 cells were analyzed for transgene expression.
(A) The image was taken under a fluorescence microscopy for
dsAAV2/GFP (A1) or dsAAV2-OVA/GFP (A2) transduction at 103
particles per cell. (B) Luciferase activity was measured after cells was
harvested and lysed with passive buffer for AAV2-OVA/luc transduc-
tion at 103 or 104 particles per cell. (C) AAT expression was detected
with ELISA in supernatant from AAV2-OVA/AAT transduction at
103 particles per cell. The results represent the means of three indi-
vidual experiment  the standard derivations.
FIG. 3. OVA epitope presentation in cells transduced with the
AAV2-OVA vector. 293 cells were transfected with 5 g of the H2Kb
plasmid and, 24 h later, the cells were incubated with AAV2-OVA/
AAT vector or AAV2/AAT vector at 105 particles/cell for 2 h. Then,
spleen cells harvested from OT-1 mice were added, followed by cocul-
ture for 24 h. CD8/CD69 or CD8/IFN-	 expression was investigated by
flow cytometry. The data represent from the results of one of three
independent experiments.
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2 
 1011 particles of AAV2-OVA/AAT i.v., and 6 weeks later
the frequency of H2Kb-OVA tetramer binding CD8 T cells
measured in the liver and spleen. As demonstrated in Fig. 5, a
marked increase in the frequency of H2Kb-OVA tetramer
binding CD8 T cells was detected in both spleen and liver of
AAV2-OVA treated mice versus animals injected with AAV2
or left untreated (Fig. 5A and B). In vivo CTL assay further
demonstrated increased CTL function in AAV2-OVA-im-
munized mice compared to the control and AAV2-immu-
nized groups (Fig. 5C).
AAV2-OVA administration enhances an established OVA-
specific CTL response. To examine the effect of AAV2-OVA
administration in mice with preexisting immunity, C57BL/6
mice were treated with SIINFEKL-pulsed DCs twice but not
three times at weekly intervals since the strongest CTL re-
sponse can be induced with three peptide-pulsed DC immuni-
zations (24). Ten days after the last treatment, 2 
 1011 par-
ticles of AAV2-OVA were injected i.v. Two weeks post-AAV
vector injection, the frequency of H2Kb-OVA tetramer bind-
ing CD8 T cells and in vivo CTL function were measured. No
CTL response was observed in AAV2-OVA treated mice with-
out prior OVA peptide immunization (Fig. 6), perhaps the
period after administration of vector was too short to elicit an
immune response. In established OVA-immunized mice,
0.73% and 3.45% of CD8 T cells bound H2Kb-OVA tetramer
in the spleens and the livers of AAV2-treated mice, respec-
tively. Although the administration of AAV2-OVA vector in-
creased tetramer-positive cells to 1.53% and 4.9% in the
spleen and liver, respectively (Fig. 6A and B, P  0.05 com-
pared to AAV-OVA vector application). Only 0.32% and
1.63% CD8 T cells stained with H2Kb-OVA tetramer in
untreated mice (Fig. 6A and B). In vivo CTL function assay
demonstrated that CTLs exerted more killing of target cells in
FIG. 4. OVA-specific CTL response was elicited with muscular
injection of AAV2-OVA vector. (A) A total of 2 
 1011 particles of
AAV2-OVA/AAT vectors were injected into muscle of C57BL
mice, and 6 weeks later the spleen cells were harvested for OVA-
specific CTL tetramer staining analyzed by flow cytometry. (B) In
vivo CTL function analysis. Spleen cells from C57BL/C mouse were
either labeled with a high concentration of CFSE (CFSEH) and
pulsed with SIINFEKL peptide or labeled with a low concentration
of CFSE (CFSEL). The mixture of both populations of target cells
were injected i.v. into AAV-OVA vector receiving mice after 6
weeks. After 24 h, single cells were isolated from the spleens and
analyzed by flow cytometry to determine the percentage of remain-
ing target cells that are either CFSEH or CFSEL, and the in vivo
CTL-mediated killing was calculated (see Materials and Methods
for more details). The number represents the in vivo CTL-specific
killing from one of four mice.
FIG. 5. OVA-specific CTL response was elicited with systemic injection of AAV2-OVA vector. A total of 2 
 1011 particles of AAV2-OVA/
AAT vectors were injected into C57BL mice via tail vein, 6 weeks later spleen cells (A) or liver cells (B) were harvested for OVA-specific CTL
tetramer staining. or an in vivo CTL function analysis was performed (C). All data represent the means from AAV vector-treated mice (n  3 or
4) and the standard derivations. *, P  0.05 versus control or AAV group.
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DC-immunized mice with AAV2-OVA vector than with AAV2
vector (87% killing versus 64%, respectively, Fig. 6C, P 
0.05). These data indicate that the administration of AAV2-
OVA vector further enhances an established CTL response
and provides additional evidence that OVA epitope can be
presented on the cell surface and induce a CTL response after
AAV2-OVA administration.
AAV2-OVA/AAT vector-transduced target cells are elimi-
nated in vivo by OVA-specific CTLs. In previous animal stud-
ies, the AAV2 capsid induced a specific CTL response, and yet
these CTLs did not eliminate AAV2-transduced cells. In con-
trast, cells with endogenous AAV2 capsid expression were
killed in vivo (12). To determine whether the increased immu-
nogenicity of the AAV2-OVA capsid resulted in killing of
transduced cells, C57BL/6 mice were treated with SIINFEKL-
pulsed DCs as described above. Ten days after the last immu-
nization, mice received i.v. 2 
 1011 particles of AAV2-OVA/
AAT. Significantly less circulating AAT was detected in mice
injected with AAV2-OVA/AAT and receiving SIINFEKL-
pulsed DCs relative to animals injected only with AAV2-OVA/
AAT (Fig. 7A). Notably, a 25% decrease of AAT was observed
in DC-treated mice one week after virus administration (P 
0.05), while a fourfold decrease was observed at week 5, com-
pared to the mice not receiving the DC pretreatment (P 
0.01). Thereafter, AAT level remained stable, suggesting that
in mice with established SIINFEKL-specific immunity the re-
duction of AAT levels was not due to immunity to AAT per se
but likely due to CTL targeting of AAV2-OVA transduced
cells. Also, we observed that the liver enzyme AST was ele-
vated in OVA-immunized mice after administration of AAV2-
OVA/AAT vector (Fig. 7B). To rule out the possibility of CTL
nonspecific mediated killing of AAV2-OVA-transduced liver
cells, mice received DCs pulsed with the HIV gag p24 peptide.
The AAT levels in blood after AAV2-OVA/AAT injection
were comparable to mice not receiving the DC transfers (Fig.
7C). These results suggest that the SIINFEKL epitope is pro-
cessed and presented on the surface of liver cells transduced by
AAV2-OVA, which in turn are killed by SIINFEKL-specific
CTLs.
DISCUSSION
In this study we have demonstrated that a CTL response was
elicited from an engineered AAV vector containing the OVA-
derived SIINFEKL peptide in the AAV2 capsid HI loop.
OVA-specific CTLs were further enhanced by administration
of AAV2-OVA vector and eliminated AAV2-OVA vector
transduced target cells in vivo. These laboratory-derived AAV
mutants will help us investigate the mechanism of AAV capsid
presentation to induce a CTL response after in vivo application
and explore novel approaches to evade immune-response-me-
diated elimination of AAV transduced target cells.
Concerns over the AAV capsid-induced CTL response have
been brought to the forefront by results from a recent clinical
trial in patients with hemophilia B after treatment with
AAV2/F9 vectors. In one patient, the therapeutic level of F9
was achieved in the blood at week 2 after injection of AAV2/
F9. Several weeks later, the F9 level plummeted to baseline
values. It was suggested that the elimination of AAV2-trans-
duced liver cells was mediated by memory CTLs against the
FIG. 6. The administration of AAV2-OVA vector further enhanced the preexisting CTL response. C57BL mice were immunized with OVA
peptide SIINFEKL-pulsed DCs twice weekly. Ten days after last DC vaccination, 2 
 1011 particles of AAV2-OVA/AAT vectors were injected
via tail vein. At 2 weeks after vector injection, the spleen and the liver were harvested for tetramer-specific CTL analysis (panels A and B,
respectively) or in vivo CTL assay was carried out (C). All data represent the mean of four mice and the standard derivation. *, P  0.05 or **,
P  0.01 (versus control or AAV2-OVA); #, P  0.05 (versus CTLAAV2).
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AAV2 capsid since the patient had low titer of neutralizing
antibodies against AAV2 in his blood before treatment and
AAV2 capsid peptide stimulated lymphocytes to secrete IFN-	
(15). Although a CTL response to AAV2 capsid has also been
confirmed in animal models, these CTLs did not clear AAV2-
transduced target cells in mice, which is inconsistent with the
interpretation of the clinical data (12, 14, 29). Attempts to
replicate these findings in transgenic mice with human HLA
gene knock-in were disappointing, since AAV2 administration
via muscular injection did not elicit a capsid specific CTL
response, which is different from what was observed in wild-
type mice (BALB/c and C57BL/c) after injection of AAV vec-
tor (13, 16, 22, 29). One possible explanation is that the AAV2
capsid is a weak antigen in animal models. In order to recreate
the observed results from the clinical trial is to enhance AAV2
capsid immunogenicity through mutagenesis, while ensuring
minimal effect on packaging capacity, infectivity, or tropism of
AAV virions.
Mutagenesis of the AAV2 capsid has been widely studied
and has provided valuable information to understand AAV2
biology and structure. Specific ligands have been incorporated
into the AAV2 virion surface via insertion or substitution to
enhance AAV2’s transduction in specific tissues. At residue
138, the N terminus of VP-2, the insertion of an expanded
serpin receptor ligand (KFNKPFVFLI) or hemagglutinin
epitope (YPYDVPDYA) or gaussia luciferase does not influ-
ence AAV2 biological characteristics including virus packag-
ing, transduction efficiency, and heparin-binding capacity (2,
32). However, insertions at residue 587 or 521 abolish the
AAV2 heparin-binding ability and changes the tissue tropism
(8, 25, 26). The HI loop of AAV2 is localized between residues
653 and 669 (VP1 numbering) based on the crystal structure
and surrounds the fivefold pore, extending from each subunit
and overlapping the underlying subunit (35). The HI loop is
present in autonomous parvoviruses, including canine parvo-
virus, porcine parvovirus, and minute virus of mice. The amino
acid sequence of the HI loop varies among different serotypes
of AAV. We inserted 4 aa into the 649 residue just before the
HI loop using linker insertion mutagenesis and demonstrated
that this mutant maintained virus morphology, stability, and
infectivity comparable to the wild-type virion (19). Recently,
we swapped the AAV2 HI loop with HI loops from other
serotypes, none of these seemed to influence the AAV2 bio-
logical profile (7). This information implicates that we can
swap AAV HI loop with a strong immunogenic domain. After
OVA epitope SIINFEKL peptide swapping, similar virus yield
and tropism were observed in vitro and in vivo compared to
wtAAV2 vector.
Several lines of evidence confirmed that OVA antigen pre-
sentation occurred after AAV2-OVA vector transduction in
vitro and in vivo. (i) AAV2-OVA vector transduced H-2Kb
cells activated spleen cells from OT-1 mice. (ii) OVA-specific
CTL reactivity was elicited after i.v. or i.m. administration of
AAV2-OVA vector into C57BL/6 mice. (iii) In preimmunized
FIG. 7. Cytotoxicity of OVA-specific CTLs on AAV2-OVA transduced cells in vivo. Mice were injected intravascularly with peptide-pulsed
DCs three times on a weekly basis. Ten days after the last immunization, 2 
 1011 particles of AAV2/OVA-AAT vectors were administered by
tail vein injection. The AAT level in the blood was detected at the indicated time points after AAV administration by ELISA. The AST in the blood
was also measured in mice. (A) The kinetics of AAT expression in the blood in OVA peptide-immunized mice with AAV2-OVA vector
administration. (B) The kinetic change of the AST in the blood in OVA peptide-immunized mice with AAV2-OVA vector administration. (C) The
AAT expression in the blood at week 6 in p24 peptide-immunized mice after AAV2-OVA vector administration. All data represent the mean
results from four mice and the standard derivation. *, P  0.05 or **, P  0.01 (versus AAV2-OVA/AAT).
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mice with OVA SIINFEKL peptide, OVA-specific CTL func-
tion was further enhanced after injection of AAV2-OVA
vector. (iv) OVA-specific CTLs eliminated AAV2-OVA trans-
duced liver cells and resulted in decreased transgene expres-
sion.
It is interesting to point out that OVA-specific CTLs were
observed in the liver at a higher level than in the spleen. This
observation is consistent to Walk’s finding after muscular in-
jection of AAV2/LacZ vector, i.e., higher number of LacZ-
specific CTLs were demonstrated in the liver than in the spleen
and muscle (28). The reason for this is that the liver is a
graveyard and holds CTLs regardless of whether the liver is the
target or not (10). It is worth noting that OVA-specific CTLs in
the liver kill AAV-OVA vector-transduced liver cells, which
mimics observations in the clinical trial. Our previous data
demonstrated that AAV capsid-specific CTLs did not kill
AAV2-transduced liver cells but that these CTLs eliminated
AAV2-transduced liver cells when the AAV2 capsid genome
was included in AAV vector transgene (12), a finding which is
consistent with the observation when OVA antigen is ex-
pressed as a vector cotransgene, killing is 100% (data not
shown). In the present study the inclusion of OVA CTL im-
munodomain SIINFEKL into AAV2 virion resulted in OVA-
specific CTL-mediated elimination of AAV2-OVA-transduced
liver cells. Again, this result further supports weak immunoge-
nicity of AAV capsid to induce a CTL response in mice.
Recently, 12 serotypes and over 100 variants of AAV have
been isolated and used as gene therapy vectors, in addition to
different tropism in vivo, the kinetics of transgene expression
delivered by different serotype vectors is different, probably
arising from differential vector trafficking and uncoating (27).
Transgene expression reaches the peak and remains stable
much earlier in vivo with AAV8 than with AAV2, possibly due
to faster uncoating of AAV8 virions than of AAV2 (27). De-
spite low neutralizing antibody cross-reactivity among AAV
serotypes, the high homology of capsid protein sequences and
observed cross-reactivity of CTL response against capsid
among AAV serotypes and variants have been documented
(14, 16). Integration of a strong immunodomain into AAV
capsid, as reported here, will permit studies focused on better
understanding of the kinetics of capsid cross-presentation for
other serotypes.
In summary, substitution of the AAV2 virion HI loop with
the OVA epitope SIINFEKL results in (i) an OVA/H2Kb
complex presented on the cell surface, (ii) OVA-specific CTL
activation, and (iii) CTL killing of AAV-OVA vector trans-
duced target cells in vivo. These data support a mechanism of
T-cell killing that follows the kinetics of capsid uncoating as
primary reason for target cell elimination. Also, the data fur-
ther confirmed our assumption that AAV capsid possesses
poor antigenicity in mice. It remains to be determined if this
weak antigenicity is or is not seen in AAV clinical studies as
observed in rodent studies. Our study demonstrates that the
utilization of an AAV-OVA vector in C57BL mice is an ideal
model developed to mimic immune responses that may also be
observed in human clinical trials. However, it should be noted
that OVA is a “super” antigen that does not exist naturally in
AAV capsid and that presentation of capsid antigen in the
setting of the present study may not represent all of the im-
mune response results observed in patients with different HLA
class I alleles. More importantly from the present study, the
application of this engineered AAV-OVA capsid now allows
preclinical studies of the kinetics of capsid antigen cross-pre-
sentation at different vector doses (as well as different sero-
types) in animal models, which should better predict the like-
lihood of safety concerns in current and future AAV clinical
trials. Not only will work from the present study directly lead to
a better understanding of the results obtained from the human
trials, but it will also create a context in which novel ap-
proaches can be tested to evade host immune response-medi-
ated elimination of AAV transduced target cells.
ACKNOWLEDGMENTS
This study was supported in part by NIH research grants
5P01GM059299, R01AI072176, and 1U54AR056953 to R.J.S. and
grant R01AI058014 to R.T. and an Alpha-1 Foundation grant to C.L.
We thank M. Bevan at the University of Washington for providing
the pCBA-OVA construct and R. Flavell at Yale University providing
the H2-Kb plasmid.
REFERENCES
1. Altman, J. D., P. A. Moss, P. J. Goulder, D. H. Barouch, M. G. McHeyzer-
Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic
analysis of antigen-specific T lymphocytes. Science 274:94–96.
2. Asokan, A., J. S. Johnson, C. Li, and R. J. Samulski. 2008. Bioluminescent
virion shells: new tools for quantitation of AAV vector dynamics in cells and
live animals. Gene Ther. 15:1618–1622.
3. Chao, H., Y. Liu, J. Rabinowitz, C. Li, R. J. Samulski, and C. E. Walsh. 2000.
Several log increase in therapeutic transgene delivery by distinct adeno-
associated viral serotype vectors. Mol. Ther. 2:619–623.
4. Chao, H., P. E. Monahan, Y. Liu, R. J. Samulski, and C. E. Walsh. 2001.
Sustained and complete phenotype correction of hemophilia B mice follow-
ing intramuscular injection of AAV1 serotype vectors. Mol. Ther. 4:217–222.
5. Chao, H., R. Samulski, D. Bellinger, P. Monahan, T. Nichols, and C. Walsh.
1999. Persistent expression of canine factor IX in hemophilia B canines.
Gene Ther. 6:1695–1704.
6. Chen, J., Q. Wu, P. Yang, H. C. Hsu, and J. D. Mountz. 2006. Determination
of specific CD4 and CD8 T-cell epitopes after AAV2- and AAV8-hF. IX
gene therapy. Mol. Ther. 13:260–269.
7. DiPrimio, N., A. Asokan, L. Govindasamy, M. Agbandje-McKenna, and R. J.
Samulski. 2008. Surface loop dynamics in adeno-associated virus capsid
assembly. J. Virol. 82:5178–5189.
8. Girod, A., M. Ried, C. Wobus, H. Lahm, K. Leike, J. Kleinschmidt, G.
Deleage, and M. Hallek. 1999. Genetic capsid modifications allow efficient
re-targeting of adeno-associated virus type 2. Nat. Med. 5:1438.
9. Girod, A., C. E. Wobus, Z. Zadori, M. Ried, K. Leike, P. Tijssen, J. A.
Kleinschmidt, and M. Hallek. 2002. The VP1 capsid protein of adeno-
associated virus type 2 is carrying a phospholipase A2 domain required for
virus infectivity. J. Gen. Virol. 83:973–978.
10. Huang, L., G. Soldevila, M. Leeker, R. Flavell, and I. N. Crispe. 1994. The
liver eliminates T cells undergoing antigen-triggered apoptosis in vivo. Im-
munity 1:741–749.
11. Kotin, R. M., R. M. Linden, and K. I. Berns. 1992. Characterization of a
preferred site on human chromosome 19q for integration of adeno-associ-
ated virus DNA by non-homologous recombination. EMBO J. 11:5071–5078.
12. Li, C., M. Hirsch, A. Asokan, B. Zeithaml, H. Ma, T. Kafri, and R. J.
Samulski. 2007. Adeno-associated virus type 2 (AAV2) capsid-specific cyto-
toxic T lymphocytes eliminate only vector-transduced cells coexpressing the
AAV2 capsid in vivo. J. Virol. 81:7540–7547.
13. Li, H., S. L. Murphy, W. Giles-Davis, S. Edmonson, Z. Xiang, Y. Li, M. O.
Lasaro, K. A. High, and H. C. Ertl. 2007. Pre-existing AAV capsid-specific
CD8 T cells are unable to eliminate AAV-transduced hepatocytes. Mol.
Ther. 15:792–800.
14. Li, H., S. L. Murphy, W. Giles-Davis, S. Edmonson, Z. Xiang, Y. Li, M. O.
Lasaro, K. A. High, and H. C. Ertl. 2007. Pre-existing AAV capsid-specific
CD8 T cells are unable to eliminate AAV-transduced hepatocytes. Mol.
Ther. 15:792–800.
15. Manno, C. S., G. F. Pierce, V. R. Arruda, B. Glader, M. Ragni, J. J. Rasko,
M. C. Ozelo, K. Hoots, P. Blatt, B. Konkle, M. Dake, R. Kaye, M. Razavi, A.
Zajko, J. Zehnder, P. K. Rustagi, H. Nakai, A. Chew, D. Leonard, J. F.
Wright, R. R. Lessard, J. M. Sommer, M. Tigges, D. Sabatino, A. Luk, H.
Jiang, F. Mingozzi, L. Couto, H. C. Ertl, K. A. High, and M. A. Kay. 2006.
Successful transduction of liver in hemophilia by AAV-factor IX and limi-
tations imposed by the host immune response. Nat. Med. 12:342–347.
16. Mingozzi, F., M. V. Maus, D. J. Hui, D. E. Sabatino, S. L. Murphy, J. E.
VOL. 83, 2009 CTL ELIMINATED AAV-TRANSDUCED CELLS IN VIVO 6823
Rasko, M. V. Ragni, C. S. Manno, J. Sommer, H. Jiang, G. F. Pierce, H. C.
Ertl, and K. A. High. 2007. CD8 T-cell responses to adeno-associated virus
capsid in humans. Nat. Med. 13:419–422.
17. Monahan, P. E., R. J. Samulski, J. Tazelaar, X. Xiao, T. C. Nichols, D. A.
Bellinger, M. S. Read, and C. E. Walsh. 1998. Direct intramuscular injection
with recombinant AAV vectors results in sustained expression in a dog
model of hemophilia. Gene Ther. 5:40–49.
18. Rabinowitz, J. E., F. Rolling, C. Li, H. Conrath, W. Xiao, X. Xiao, and R. J.
Samulski. 2002. Cross-packaging of a single adeno-associated virus (AAV)
type 2 vector genome into multiple AAV serotypes enables transduction with
broad specificity. J. Virol. 76:791–801.
19. Rabinowitz, J. E., W. Xiao, and R. J. Samulski. 1999. Insertional mutagen-
esis of AAV2 capsid and the production of recombinant virus. Virology
265:274–285.
20. Romano, G. 2005. Current development of adeno-associated viral vectors.
Drug News Perspect. 18:311–316.
21. Rose, J. A., J. V. Maizel, Jr., J. K. Inman, and A. J. Shatkin. 1971. Structural
proteins of adenovirus-associated viruses. J. Virol. 8:766–770.
22. Sabatino, D. E., F. Mingozzi, D. J. Hui, H. Chen, P. Colosi, H. C. Ertl, and
K. A. High. 2005. Identification of mouse AAV capsid-specific CD8 T-cell
epitopes. Mol. Ther. 12:1023–1033.
23. Samulski, R. J., K. I. Berns, M. Tan, and N. Muzyczka. 1982. Cloning of
adeno-associated virus into pBR322: rescue of intact virus from the recom-
binant plasmid in human cells. Proc. Natl. Acad. Sci. USA 79:2077–2081.
24. Serody, J. S., E. J. Collins, R. M. Tisch, J. J. Kuhns, and J. A. Frelinger.
2000. T-cell activity after dendritic cell vaccination is dependent on both the
type of antigen and the mode of delivery. J. Immunol. 164:4961–4967.
25. Shi, W., and J. S. Bartlett. 2003. RGD inclusion in VP3 provides adeno-
associated virus type 2 (AAV2)-based vectors with a heparan sulfate-inde-
pendent cell entry mechanism. Mol. Ther. 7:515–525.
26. Shi, X., G. Fang, W. Shi, and J. S. Bartlett. 2006. Insertional mutagenesis at
positions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene
and generation of AAV2 vectors with eliminated heparin-binding ability and
introduced novel tropism. Hum. Gene Ther. 17:353–361.
27. Thomas, C. E., T. A. Storm, Z. Huang, and M. A. Kay. 2004. Rapid uncoating
of vector genomes is the key to efficient liver transduction with pseudotyped
adeno-associated virus vectors. J. Virol. 78:3110–3122.
28. Velazquez, V. M., D. G. Bowen, and C. M. Walker. 2009. Silencing of T
lymphocytes by antigen-driven programmed death in recombinant adeno-
associated virus vector (rAAV)-mediated gene therapy. Blood 113:538–545.
29. Wang, L., J. Figueredo, R. Calcedo, J. Lin, and J. M. Wilson. 2007. Cross-
presentation of adeno-associated virus serotype 2 capsids activates cytotoxic
T cells but does not render hepatocytes effective cytolytic targets. Hum.
Gene Ther. 18:185–194.
30. Warrington, K. H., Jr., O. S. Gorbatyuk, J. K. Harrison, S. R. Opie, S.
Zolotukhin, and N. Muzyczka. 2004. Adeno-associated virus type 2 VP2
capsid protein is nonessential and can tolerate large peptide insertions at its
N terminus. J. Virol. 78:6595–6609.
31. Warrington, K. H., Jr., and R. W. Herzog. 2006. Treatment of human disease
by adeno-associated viral gene transfer. Hum. Genet. 119:571–603.
32. Wu, P., W. Xiao, T. Conlon, J. Hughes, M. Agbandje-McKenna, T. Ferkol, T.
Flotte, and N. Muzyczka. 2000. Mutational analysis of the adeno-associated
virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with
altered tropism. J. Virol. 74:8635–8647.
33. Wu, Z., A. Asokan, and R. J. Samulski. 2006. Adeno-associated virus sero-
types: vector toolkit for human gene therapy. Mol. Ther. 14:316–327.
34. Xiao, X., J. Li, and R. J. Samulski. 1998. Production of high-titer recombi-
nant adeno-associated virus vectors in the absence of helper adenovirus.
J. Virol. 72:2224–2232.
35. Xie, Q., W. Bu, S. Bhatia, J. Hare, T. Somasundaram, A. Azzi, and M. S.
Chapman. 2002. The atomic structure of adeno-associated virus (AAV-2), a
vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99:10405–10410.
6824 LI ET AL. J. VIROL.
